Compositions and methods for neurological diseases

A technique of combining and combining structural domains, which can be applied to neurological diseases, chemical instruments and methods, receptors of neurotransmitters, etc., and can solve the problems that gene therapy has not been widely used to treat neurological diseases

Pending Publication Date: 2022-07-12
科达生物治疗医药有限公司
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, to date, gene therapy has not b...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for neurological diseases
  • Compositions and methods for neurological diseases
  • Compositions and methods for neurological diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0372] Example 1. Discovery of Mutated Engineered Receptors Containing a Ligand Binding Domain

[0373] To generate LGICs that conduct anion currents upon exposure to unnatural small-molecule agonists of human α7-nAChR, chimeric ligand-gated ion channel (LGIC) receptors were genetically engineered, containing receptors derived from human α7 nicotinic acetylcholine receptors. A ligand-binding domain (α7-nAChR) derived and a chloride-conducting ionopore domain derived from human GlyR1α. An engineered receptor with the amino acid sequence of SEQ ID NO: 33 was identified that was approximately as sensitive to acetylcholine, ABT-126, and TC-6987 as wild-type α7-nAChR, with TC-6987 showing similar Partial agonist activity on SEQ ID NO:33. Compared to wild type, SEQ ID NO:33 was about 2-fold less sensitive to nicotine and about 3-fold and 10-fold more sensitive to AZD-0328 and Facinicline / RG3487, respectively.

[0374] Amino acid substitutions were introduced into the ligand bindin...

Embodiment 2

[0376] Example 2: Characterization of engineered receptors using high-throughput fluorescence-based plate screening

[0377]To screen these mutant LGICs for those with novel responsive properties to ligands, an anion reporter assay was developed to assess channel function in a high-throughput format. In this assay, cells expressing a YFP reporter whose fluorescence is quenched in the presence of anions are transfected with DNA encoding the channel of interest. Upon exposure to the ligand, the activated channel will efflux anions, resulting in a dose-dependent quenching of YFP detectable on a plate reader.

[0378] Lenti-X 293T cells (LX293T, Clontech) were maintained in DMEM (Invitrogen) containing 10% FBS and 1% penicillin / streptomycin. For the plate reader assay, LX293T cells were infected with lentivirus to establish cells stably expressing the mutant YFP (H148Q / I152L) reporter, which showed enhanced sensitivity to anions. Two days before the assay, cells were aliquoted i...

Embodiment 3

[0382] Example 3: Characterization of engineered receptors using high-throughput electrophysiology

[0383] To confirm EC determined by plate reader 50 As well as a better understanding of the formation of maximal currents, a high-throughput electrophysiology system is performed on engineered receptors as described below. For HEK293T studies, the cDNA encoding the ion channel was cloned into pcDNA3.1 using standard recombinant techniques. HEK293T cells from Clontech (Lenti-X TM 293T cell line) were grown to 40-50% confluency in DMEM supplemented with 10% FBS and 1% penicillin / streptomycin and transfected with ion channel plasmids at a concentration of 18 μg per 15 cm dish using Fugene 6 and grown Another 24 hours. Cells were then assayed on an electrophysiology system (IonFluxHT and / or Mercury, Fluxion Biosciences), where dose-response relationships could be assessed by a microfluidic-based platform for establishing whole-cell configurations. with extracellular buffer (140...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Compositions and methods are provided for modulating cell activity using engineered receptors, engineered receptors encoded by polynucleotides, and gene therapy vectors comprising polynucleotides encoding engineered receptors. These compositions and methods are particularly useful for modulating the activity of neurons, such as in the treatment of disease or in the study of neuronal circuits.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of US Provisional Patent Application Serial No. 62 / 889,963, filed August 21, 2019, the contents of which are incorporated herein by reference in their entirety. [0003] Description of Electronically Submitted Text File [0004] The Sequence Listing pertaining to this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference into the specification. The name of the text file containing the sequence listing is "SWCH02901WO-Sequence_Listing". The text file is 200kb, created on August 21, 2020, and is being submitted electronically via EFS-Web. technical field [0005] The present disclosure relates to engineered receptors and the use of engineered receptors and small molecule ligands for modulating cellular activity and treating disease. Background technique [0006] Intractable neurological diseases are often associated with abnormally ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K19/00C07K14/705C12N15/62A61K38/17A61K45/06A61P25/02A61P25/04A61P25/06
CPCC07K14/70571A61K38/1787A61K45/06A61P25/02A61P25/04A61P25/06A61K38/00C07K2319/00A61P25/22A61P25/24A61P25/08A61P25/16A61P1/04A61K48/005C07K14/705
Inventor S·梅金森小安东尼·刘小俄里翁·P·开菲尔
Owner 科达生物治疗医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap